- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04805684
Different Lung Ultrasound Imaging Protocols in COVID-19 Pneumonia
March 17, 2021 updated by: Korgün Ökmen, Bursa Yüksek İhtisas Education and Research Hospital
Comparison of Two Different Lung Ultrasound Imaging Protocols in COVID -19 Pneumonia
Lung ultrasonography (LUS) is also used in COVID 19 pneumonia for diagnostic and follow-up purposes.It has been demonstrated in different studies that it can be used for pathologies in pleural and lung tissue.
LUS was applied by different researchers by dividing the lungs into 12 and 14 regions and the results were shared.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
In our study, we aimed to determine the correlation between lung findings of COVID 19 pneumonia and thoracic tomography with the results of LUS applied to different numbers (12 versus 14) of areas.
Study Type
Interventional
Enrollment (Actual)
59
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bursa, Turkey
- University of Health Sciences, Bursa Yuksek Ihtisas Training and Research Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 18 and 85 years old
- Hospitalized in intensive care unit
- PCR (polymerase chain reaction) tested
- Thoracic CT applied
Exclusion Criteria:
- Previous lung operation
- Thoracic wall disorder
- Interstitial lung disease
- Patients who did not consent to participate in the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: lung ultrasound 12
12 zone lung ultrasonography protocol
|
Application of 12 areas (2 posterior, 2 lateral, and 2 anterior)lung ultrasonography protocol using the convex ultrasound probe (2-6 MHz)
|
Active Comparator: lung ultrasound 14
14 zone lung ultrasonography protocol
|
Application of 14 areas (3 posterior, 2 lateral, and 2 anterior) lung ultrasonography protocol using the convex ultrasound probe (2-6 MHz)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation between Thoracic CT imaging results and LUS results
Time Frame: 6 hours
|
Lung ultrasonography will be performed within 6 hours of the Thoracic CT.
|
6 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Characteristics of lesions
Time Frame: 6 hours
|
Identifying the characteristics of the abnormal findings detected in Thoracic CT and LUS
|
6 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2021
Primary Completion (Actual)
March 5, 2021
Study Completion (Actual)
March 5, 2021
Study Registration Dates
First Submitted
March 15, 2021
First Submitted That Met QC Criteria
March 17, 2021
First Posted (Actual)
March 18, 2021
Study Record Updates
Last Update Posted (Actual)
March 18, 2021
Last Update Submitted That Met QC Criteria
March 17, 2021
Last Verified
March 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2011-KAEK-25 2021
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pneumonia
-
King Edward Memorial HospitalCompletedNosocomial Pneumonia | Healthcare-Associated Pneumonia | Aspiration Pneumonia | Ventilator-Associated PneumoniaIndia
-
Melinta Therapeutics, Inc.WithdrawnHospital-Acquired Bacterial Pneumonia | Ventilator-Associated Bacterial Pneumonia | Hospital-Acquired Pneumonia | Ventilator-Associated Pneumonia
-
Venatorx Pharmaceuticals, Inc.Biomedical Advanced Research and Development AuthorityNot yet recruitingHospital-acquired Pneumonia | Ventilator-associated Pneumonia
-
University Medical Centre LjubljanaUniversity of Ljubljana, Faculty of MedicineUnknownCommunity Acquired Pneumonia | Ventilator Associated Pneumonia | Hospital Acquired PneumoniaSlovenia
-
Hannover Medical SchoolCharite University, Berlin, Germany; University of LeipzigUnknownCOVID-19 | Bacterial Pneumonia | Viral Pneumonia | Pneumonia Due to Streptococcus Pneumoniae | Pneumonia Due to H. Influenzae | Pneumonia, Organism Unspecified | Pneumonia in Diseases Classified Elsewhere | Pneumonia Due to Other Specified Infectious OrganismsGermany
-
Nantes University HospitalSociété Française d'Anesthésie et de RéanimationCompletedPneumonia | Sepsis | Ventilator-Associated Pneumonia | Hospital Acquired PneumoniaFrance
-
PfizerCompletedVentilator-associated Pneumonia (VAP) | Nosocomial Pneumonia (NP)Bulgaria, France, Italy, Korea, Republic of, Mexico, Peru, Poland, Russian Federation, Spain, Turkey, United Kingdom, Vietnam, Philippines, China, Ukraine, Argentina, Brazil, Hungary, Romania, India, Japan, Taiwan, Latvia, Czechia, Slov... and more
-
Arpida AGTerminatedHospital-Acquired Pneumonia | Ventilator-Associated Pneumonia | Health-Care-Associated Pneumonia
-
Hu YinanEnrolling by invitationSialic Acid | Superoxide Dismutase | Lipid PneumoniaChina
-
ShionogiCompletedHospital Acquired Pneumonia (HAP) | Healthcare-associated Pneumonia (HCAP) | Ventilator Associated Pneumonia (VAP)Israel, Spain, United States, Belgium, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Japan, Latvia, Philippines, Puerto Rico, Russian Federation, Serbia, Taiwan, Ukraine
Clinical Trials on LUS Twelve area
-
Royal University Hospital, SaskatoonCompletedno ConditionsCanada
-
KU LeuvenUnknownPneumonia, Viral | Pneumonia | Pregnancy Related | Pregnancy, High Risk | COVID | Diagnoses Disease | Pregnancy Complications, Infectious | Pregnancy DiseaseBelgium, Italy, United Kingdom
-
Uppsala University HospitalEnrolling by invitationUltrasonography | Thoracic SurgerySweden
-
Centre Hospitalier Universitaire de NiceUnknown
-
University Hospital, ToursNot yet recruitingRheumatoid Arthritis | Interstitial Lung Disease | Lung Ultrasound | Thoracic UltrasoundFrance
-
University of MonastirRecruitingDyspnea | Decompensated Heart Failure ; COPD ExacerbationTunisia
-
Rush University Medical CenterCompletedCovid19 | ARDSUnited States
-
Odense University HospitalCompletedColorectal CancerDenmark
-
IRCCS Fondazione Stella MarisUniversity of Pisa; Ministry of Health, Italy; Fondazione C.N.R./Regione Toscana...RecruitingCerebral Palsy | Developmental Disability | Pediatric Neurological DisorderItaly
-
Centre Hospitalier Universitaire de NiceCentre Hospitalier Princesse GraceUnknownCommunity-acquired Pneumonia